

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peter Bjorquist <i>et al.</i>)	Confirmation No. 8143
)	
Application No. 10/578,022)	Group Art Unit: 1654
)	
Filed: March 6, 2007)	Examiner: Julie Ha
)	
For: Use of Anabaenopeptin-type Peptides for the)	
Treatment of a Condition Where Inhibition)	
of Carboxypeptidase U is Beneficial, Novel)	
Anabaenopeptin Derivatives and)	
Intermediates Thereof)	Date: June 12, 2008


RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action dated May 12, 2008, the time for responding to which extends through June 12, 2008, Applicants elect without traverse the invention of Group I (*i.e.*, method claims 1, 5, 6, 16, 17 and 22). Compound 1 (as depicted on page 20 of the specification) is elected without traverse as a single disclosed species of formula (I) for examination purposes.

Except for issues payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **June 12 2008**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel: 202-739-3000
Fax: 202-739-3001

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801